$1M EBITDA Business Intelligence & Analytics Company in Little Rock

 profile

September 18, 2025

by an intermediary in Philadelphia, PA, USA

Our sell-side partner just sent us a 20+ year old Business Intelligence & Analytics company with a rock-solid track record and untapped growth potential. Key Highlights: • Revenue (2024): $1.62M • Adjusted EBITDA Margin: ~63% • Recurring Revenue: 63% (3-year median contracts, upfront annual payments) • Customer Retention: 94% • Debt-Free Balance Sheet • YoY Growth: 9.3% • High Client Retention & Continuity: 60% of customers have 2+ years left on contracts • Top 10 customers = 67% of 2025 revenue (owners will transition 1–2 years to ensure smooth handoff) Growth Levers: • Minimal paid marketing to date (primarily organic & referrals). • Certified partner with a Gartner-recognized analytics leader – strong co-marketing & deal flow. • Expansion opportunities in new verticals (pain management, orthopedics, surgical sciences, urology, etc.). • Industry tailwinds: $72B projected BI/analytics spend (2025–2026). Valuation: • Seeking a 3x–4x EBITDA multiple. • Strong upside for a growth-minded buyer to scale via marketing, channel partnerships, and vertical expansion. Why This Deal Stands Out: This is a rare chance to acquire a profitable, high-retention analytics platform with proven systems, sticky long-term contracts, and a loyal customer base. The owners are committed to a 1–2 year transition to ensure continuity and knowledge transfer. If you’re an acquisition entrepreneur, search fund, or investor interested in learning more, feel free to DM me for the teaser & introduction to broker.
1
8
471
Replies
8
commentor profile
Reply by a searcher
from University of Melbourne in Melbourne VIC, Australia
Interested, ^redacted‌. Requested NDA.
commentor profile
Reply by an intermediary
in Philadelphia, PA, USA
We specialize in raising capital deal by deal for acquisitions just like this one. That’s how this came across our plate with the sell-side firm.
commentor profile
+6 more replies.
Join the discussion